Wall Street Zen Downgrades QIAGEN (NYSE:QGEN) to Hold

QIAGEN (NYSE:QGEN) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Friday.

A number of other brokerages have also recently weighed in on QGEN. Bank of America upped their price target on QIAGEN from $50.00 to $53.00 and gave the company a “buy” rating in a research report on Thursday, June 26th. Barclays set a $53.00 price target on QIAGEN and gave the company an “overweight” rating in a research report on Thursday. Weiss Ratings reiterated a “hold (c+)” rating on shares of QIAGEN in a research report on Saturday, September 27th. Cowen reiterated a “hold” rating on shares of QIAGEN in a research report on Thursday, August 7th. Finally, UBS Group upped their price target on QIAGEN from $48.00 to $50.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, QIAGEN currently has a consensus rating of “Hold” and a consensus price target of $49.40.

QIAGEN Stock Up 1.3%

QGEN opened at $46.83 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The business has a 50 day moving average price of $47.43 and a 200 day moving average price of $45.28. The firm has a market cap of $10.41 billion, a P/E ratio of 27.67, a price-to-earnings-growth ratio of 2.47 and a beta of 0.66. QIAGEN has a twelve month low of $37.63 and a twelve month high of $51.88.

QIAGEN (NYSE:QGEN) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, hitting the consensus estimate of $0.60. The company had revenue of $533.54 million for the quarter, compared to the consensus estimate of $523.97 million. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The company’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.55 EPS. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Research analysts forecast that QIAGEN will post 2.26 EPS for the current year.

Hedge Funds Weigh In On QIAGEN

A number of institutional investors and hedge funds have recently bought and sold shares of QGEN. Wealth Enhancement Advisory Services LLC acquired a new position in QIAGEN in the fourth quarter worth $202,000. GAMMA Investing LLC lifted its stake in shares of QIAGEN by 7,684.0% during the first quarter. GAMMA Investing LLC now owns 118,161 shares of the company’s stock valued at $4,744,000 after acquiring an additional 116,643 shares during the period. Exchange Traded Concepts LLC lifted its stake in shares of QIAGEN by 2.3% during the first quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company’s stock valued at $716,000 after acquiring an additional 395 shares during the period. Bank Pictet & Cie Europe AG acquired a new position in shares of QIAGEN during the first quarter valued at $669,000. Finally, Blue Trust Inc. lifted its stake in shares of QIAGEN by 30.5% during the first quarter. Blue Trust Inc. now owns 13,519 shares of the company’s stock valued at $543,000 after acquiring an additional 3,157 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.